Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 52
- Press Release
- Press Release PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
- PharmAbcine
- 24 May 2023
- Views229
- 0
- 51
- Press Release
- Press Release PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
- PharmAbcine
- 13 Dec 2022
- Views1586
- 0
- 50
- Press Release
- Press Release PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week
- PharmAbcine
- 9 Dec 2022
- Views1097
- 0
- 49
- Press Release
- Press Release PharmAbcine to participate in Jefferies 2022 London Healthcare Conference
- PharmAbcine
- 25 Oct 2022
- Views784
- 0
- 48
- Press Release
- Press Release PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022
- PharmAbcine
- 18 Oct 2022
- Views1045
- 0
- 47
- Press Release
- Press Release PharmAbcine to Participate in BIO-Europe 2022
- PharmAbcine
- 27 Sep 2022
- Views675
- 0
- 46
- Press Release
- Press Release PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals
- PharmAbcine
- 1 Sep 2022
- Views761
- 0
- 45
- Press Release
- Press Release PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention
- PharmAbcine
- 12 May 2022
- Views1479
- 0
- 44
- Press Release
- Press Release PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study
- PharmAbcine
- 27 Apr 2022
- Views1422
- 0
- 43
- Press Release
- Press Release PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology
- PharmAbcine
- 27 Apr 2022
- Views1341
- 0